Xenetic Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Xenetic Biosciences has a total shareholder equity of $7.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $8.0M and $1.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$6.84m |
| Equity | US$7.04m |
| Total liabilities | US$1.01m |
| Total assets | US$8.05m |
Recent financial health updates
Recent updates
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Xenetic Biosciences reports Q2 results
Aug 12Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer
Aug 02Xenetic inks clinical manufacturing contract with Catalent
Jul 07Xenetic Biosciences reports Q3 results
Nov 13Financial Position Analysis
Short Term Liabilities: XBIO's short term assets ($7.0M) exceed its short term liabilities ($1.0M).
Long Term Liabilities: XBIO has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: XBIO is debt free.
Reducing Debt: XBIO had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XBIO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: XBIO has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 4.5% each year.